RenovoRx (Nasdaq:RNXT) announced today that it closed a private placement worth gross proceeds of approximately $11.1 million. The $11.1 million adds to a separate private placement that brought in proceeds of approximately $6.1 million in January. RenovoRx plans to use the funds to strengthen its balance sheet and extend its cash runway into 2026. Funds […]
Oncology
Carthera enrolls first patient in ultrasound drug delivery trial
Carthera announced today that it enrolled the first patient in the SONOBIRD pivotal trial for its SonoCloud device. Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery. After implantation in the skull, […]
RenovoRx closes $6.1M private placement
RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million. Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds […]
UroGen to raise $120M to support sustained release hydrogel delivery platform
UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]
RenovoRx, Imugene collab on oncolytic virus therapy delivery
RenovoRx (Nasdaq:RNXT) announced that it entered into a strategic research collaboration with Imugene to optimize oncolytic virus therapy delivery. Utilizing RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform), the companies hope to enhance the treatment of difficult-to-access tumors. “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally […]
This biodegradable brain implant delivers cancer-treating drugs
Researchers say they developed a biodegradable brain implant capable of helping to deliver chemotherapy drugs directly to tumors. Medscape News reported that the research marks another step toward using ultrasound to combat cancer. According to the team, led by Thanh Nguyen, these drugs can penetrate the blood-brain barrier to reach these brain tumors. Nguyen serves […]
Researchers use skull-implantable ultrasound to help deliver chemotherapy to the brain
Northwestern Medicine shared results from a first-in-human clinical trial for a skull-implantable ultrasound device that supports chemotherapy delivery. The device opened the blood-brain barrier to repeatedly permeate large, critical regions of the human brain. This enabled the delivery of chemotherapy injected intravenously. With the patient awake, a four-minute procedure opens the blood-brain barrier and patients […]
Researchers use tiny drug delivery implant to treat tumors
Researchers at Houston Methodist Research Institute developed a tiny drug delivery device for addressing difficult-to-treat cancers. The researchers published their work in a paper in Advanced Science. They used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAB). The team calls the device a nanofluidic drug-eluting seed (NDES). With the device — […]
Medtech veteran Tatyana Beldock joins Dyve Biosciences board
Dyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors. Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation. “We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings […]
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
